TOKYO, Dec. 19, 2023 /PRNewswire/ — Kaigai FX Online, a prominent resource for international foreign exchange trading, is pleased to announce the winners of its 2nd Grand Prix for foreign FX brokers. This prestigious award spotlights brokers that deliver exceptional service in the competitive world of currency trading, with a particular focus on cost-effectiveness and strategic trading options like high leverage and scalping.

The 2nd announcement of the foreign FX broker awards by Kaigai FX Online

Tradeview Clinches the 2023 Lowest Trading Costs Broker Award

After a survey involving 500 seasoned foreign FX traders, Tradeview emerged victorious, securing the Grand Prix in the "Lowest Trading Costs Broker Award 2023." The survey highlighted that traders value not just a broker’s market presence and brand recognition, but also the importance of low trading costs when making their choice.

For more details on Tradeview’s award, visit:

https://emotional-link.co.jp/kaigaifx/commendation-tradeview/

https://surfsup.tradeviewforex.com/todays-waves/gold-surges-to-multi-month-high-as-biden-arrives-in-israel/

TradersTrust Awarded for Highest Leverage & Scalping Suitability in 2023

The survey also underscored the allure of foreign FX—the potential for substantial short-term gains through the use of high leverage. Recognizing the best in this arena, the "Highest Leverage & Most Suitable for Scalping Broker Award 2023" was awarded to TradersTrust. This accolade honors the broker’s superior offerings that cater to traders who employ high leverage and scalping strategies.

For further information on TradersTrust’s commendation, visit:

https://emotional-link.co.jp/kaigaifx/commendation-traderstrust/

https://traders-trust.com/ja/awarded-for-highest-leverage-most-suitable-for-scalping/

Explore these resources to enhance your trading experience:

Kaigai FX Online aims to support traders, from beginners to intermediate and professionals, in finding suitable foreign FX brokers. The website provides information such as evaluations of various brokers, including Tradeview, and TradersTrust.  Additional resources such as the "Truly Recommended Foreign FX Brokers Ranking" and "Latest Bonus Information for Foreign FX Brokers" are also available, meticulously curated from a pool of 80 companies.

Explore these resources to enhance your trading experience:

https://emotional-link.co.jp/kaigaifx/broker-recommend-ranking/

https://emotional-link.co.jp/kaigaifx/bonus-hikaku/

https://emotional-link.co.jp/kaigaifx/deposit-bous/

or more information, please visit https://emotional-link.co.jp/kaigaifx/ or follow their Twitter official account(@kaigaifx_online).

Source : Kaigai FX Online Unveils Winners of the 2nd Annual Grand Prix for Exceptional Foreign FX Brokers

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Dec. 19, 2023 /PRNewswire/ — Ricoh, a global leader in digital services, imaging, and IT, has been recognised by Cisco as the Asia Pacific SMB Managed Service Partner of the Year for its exceptional commitment to delivering innovative and reliable managed services tailored to the unique needs of small and medium-sized businesses.

The Cisco Asia Pacific SMB Awards, announced Dec.05 at Cisco Live in Melbourne, Australia, reflect the top-performing partners within specific technology markets and segments across the Asia Pacific region. Award recipients are selected by a committee of executives representing Cisco’s Global and Regional Partner Sales Organizations.

"Our partnership with Cisco enables us to deliver unparalleled levels of innovation to our clients, maximising their investments in networking and data centre modernisation," said Kei Uesugi, Managing Director for Ricoh Asia-Pacific and Latin America. "Ricoh’s expertise in digital transformation, hybrid workplaces and the entire IT spectrum allows us to tailor solutions using the best mix of products and technologies to meet the evolving needs of our SMB customers so that they can focus on running their businesses."

Together, Ricoh and Cisco help companies to scale efficiently, reduce development costs and risks, and quicken the time-to-value of new business solutions by making it easy for organisations to stay connected and productive while ensuring their networks and devices are secure and reliable.

"The theme at Cisco Live in Melbourne 2023 was ‘Let’s Go,’ and winners of the SMB Awards are fantastic examples of how we partner to achieve shared success in various regions of the world," said Michiko Kamata, Managing Director of Cisco Distribution & SMB Sales, Asia Pacific, Japan & Greater China. "I am pleased to recognise Ricoh as the winner of the Asia Pacific SMB Managed Service Partner of the Year 2023, further underscoring their outstanding accomplishments in the Asia Pacific region."

| About Ricoh |

Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support the digital transformation of workplaces and workspaces, and optimise business performance.

Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organisational capabilities nurtured over its 85-year history. In the financial year ended March 2023, Ricoh Group had worldwide sales of 2,134 billion yen (approx. 16.0 billion USD).

It is Ricoh’s mission and vision to empower individuals to find Fulfillment through Work by understanding and transforming how people work so we can unleash their potential and creativity to realise a sustainable future.

For further information, please visit www.ricoh.com

###

© 2023 RICOH ASIA PACIFIC PTE LTD. All rights reserved. All referenced product names are the trademarks of their respective companies.

Ragavan Satkunam (second right), Head of Digital Services RICOH APAC receives the ‘Asia Pacific SMB Managed Service Partner of the Year’ award from Cisco representatives Andrew Sage, VP, Global Distribution & SMB Sales (first left), Michiko Kamata, Managing Director of Cisco Distribution & SMB Sales, Asia Pacific, Japan & Greater China (second left) and David West, SVP and President of Asia Pacific, Japan, and Greater China (first right) at Cisco Live in Melbourne, Australia.

Source : Ricoh wins Asia Pacific SMB Managed Service Partner of the Year

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

The captivating Indian superstar comes face-to-face with his new figures, launching in the Singapore and London attractions

SINGAPORE, Dec. 19, 2023 /PRNewswire/ — Bollywood’s golden boy Ranveer Singh meets not one, but two, figures of himself at Madame Tussauds.

The international star, known for box-office-breaking performances, unapologetic personal style and magnetic personality, visited the world-famous attraction in London to welcome his two new figures. He was accompanied by his mother, who, as a child, first introduced the would-be megastar to the world of Madame Tussauds London by showing him album pictures of her own visits to the iconic attraction. This is the first time the Bollywood star has been immortalised by Madame Tussauds and guests will be able to meet his new figures at Madame Tussauds’ Singapore and London attractions.

Singh’s rise to fame was nothing short of iconic, with a streak of back-to-back blockbuster hits, solidifying him as a much-loved staple of Bollywood. He has starred in many awe-inspiring films internationally, from his acting debut in Band Baaja Baaraat (2010) to beloved films Bajirao Mastani (2015), Padmaavat (2018), and Gully Boy (2019). Maintaining his high-octane presence in India for over a decade, the star has appeared in Forbes India’s Celebrity 100 list every year since 2012 and has been celebrated by GQ, India Today, and The Indian Express as one of the nation’s top 50 most influential and powerful people.

Ranveer Singh was involved throughout the creative process and specifically chose the distinct looks and styling for his figures. The Singapore figure dons a gorgeous custom tuxedo featuring a velvet blazer with floral embellishments. Designed by Gaurav Gupta and worn by Ranveer to the Hello! Hall of Fame Awards, it was graciously donated for the figure to wear by Ranveer himself. The London figure pays homage to Ranveer’s culture and heritage with the neon sherwani designed by Manish Arora as part of his wedding celebrations. The eye-catching outfit includes hundreds of individually sewn embellishments and flamboyant leopard head shoulder detail, tied together with a triple-layered diamond and pearl necklace, and eight large gemstone set rings.

The figure was originally announced in 2019 when the actor received the Madame Tussauds of the Future Award at the IIFAs – the International Indian Film Academy – where it was revealed that he would be joining the star-studded attraction. Fans have been eagerly awaiting the launch of the figure ever since and today’s news confirms the arrival of not just one but two new figures of the global superstar.

On seeing two of his first-ever figures from the attraction, Ranveer Singh said: "As a child my Mother first told me about Madame Tussauds. Ever since a young age, I’ve had a fascination for this mythical, magical place called Madame Tussauds and it’s been incredible to see how the journey of life works… What an incredible moment it is for me to be here with my Mum, launching my own figure at Madame Tussauds London. It’s a hugely proud moment for me and for my family. It is a significant achievement to have your figure at Madame Tussauds because the attraction recognises excellence in each respective field, so to be in such an esteemed company feels really wonderful. I feel very happy, very humble, very grateful and very very proud."

Andre Timmins, Co-Founder of the IIFA, said "It is so exciting for IIFA to be a part of this unveiling for Ranveer’s Madame Tussauds’ figure launch as it was at the 2011 IIFA Awards, Toronto where he won his first Best Debutant Award, and said on stage that "this is just the beginning". Like IIFA, it truly was just the start of a soaring career, and we are proud as a brand to have been able to take an icon of Indian Cinema and the fraternity to such new heights, with global recognition, and such as being honoured at Madame Tussauds London."

Ranveer’s Singapore figure is available for guests to meet from Saturday the 23rd of December within the IIFA Awards Experience zone at Madame Tussauds Singapore. He will star alongside other well-known celebrity figures such as Virat Kohli, Karan Johar, Michael Jackson, Priyanka Chopra and many more.

Ranveer’s London figure is available for guests to meet in the attraction from Monday 18th December as the Bollywood superstar joins Madame Tussauds London’s star-studded line-up alongside the likes of Dwayne ‘The Rock’ Johnson, Beyonce, Cristiano Ronaldo, Deepika Padukone and 150 other incredibly lifelike celebrity figures.

Instagram: @MTsSingapore
Facebook: @MadameTussaudsSingapore
TikTok: @MTsSingapore
Twitter: @MtsSingapore

Notes to editors:

Madame Tussauds Singapore
Located at Imbiah Lookout, Sentosa, Madame Tussauds Singapore features a variety of interactive experiences under one roof, which includes Images of Singapore, "Spirit of Singapore" boat ride – the only Madame Tussauds site to have a boat ride, the Marvel Universe 4D Cinema, and lastly the Ultimate Film Star Experience! Featuring more than 80 wax figures throughout 12 incredible zones – from glamourous Hollywood actors to your favourite Bollywood stars, musicians to sports heroes! Madame Tussauds Singapore is so much more than an exciting attraction! For more information, visit www.madametussauds.com/singapore.

About Merlin Entertainments
Merlin Entertainments is a global leader in location-based, family entertainment. As Europe’s Number 1 and the world’s second-largest visitor attraction operator, Merlin operates 137 attractions, 22 hotels and 6 holiday villages in 24 countries and across 4 continents. Merlin’s purpose is to deliver memorable experiences to its millions of guests around the world, through its iconic brands and multiple attraction formats, and the commitment and passion of its employees. See www.merlinentertainments.biz for more information and follow on Twitter @MerlinEntsNews

Source : RANVEER SINGH LAUNCHES NEW MADAME TUSSAUDS FIGURES

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Dec. 19, 2023 /PRNewswire/ — Ricoh, a global leader in digital services, imaging, and IT, has been recognised by Cisco as the Asia Pacific SMB Managed Service Partner of the Year for its exceptional commitment to delivering innovative and reliable managed services tailored to the unique needs of small and medium-sized businesses.

Ragavan Satkunam (second right), Head of Digital Services RICOH APAC receives the ‘Asia Pacific SMB Managed Service Partner of the Year’ award from Cisco representatives Andrew Sage, VP, Global Distribution & SMB Sales (first left), Michiko Kamata, Managing Director of Cisco Distribution & SMB Sales, Asia Pacific, Japan & Greater China (second left) and David West, SVP and President of Asia Pacific, Japan, and Greater China (first right) at Cisco Live in Melbourne, Australia.

The Cisco Asia Pacific SMB Awards, announced Dec.05 at Cisco Live in Melbourne, Australia, reflect the top-performing partners within specific technology markets and segments across the Asia Pacific region. Award recipients are selected by a committee of executives representing Cisco’s Global and Regional Partner Sales Organizations.

"Our partnership with Cisco enables us to deliver unparalleled levels of innovation to our clients, maximising their investments in networking and data centre modernisation," said Kei Uesugi, Managing Director for Ricoh Asia-Pacific and Latin America. "Ricoh’s expertise in digital transformation, hybrid workplaces and the entire IT spectrum allows us to tailor solutions using the best mix of products and technologies to meet the evolving needs of our SMB customers so that they can focus on running their businesses."

Together, Ricoh and Cisco help companies to scale efficiently, reduce development costs and risks, and quicken the time-to-value of new business solutions by making it easy for organisations to stay connected and productive while ensuring their networks and devices are secure and reliable.

"The theme at Cisco Live in Melbourne 2023 was ‘Let’s Go,’ and winners of the SMB Awards are fantastic examples of how we partner to achieve shared success in various regions of the world," said Michiko Kamata, Managing Director of Cisco Distribution & SMB Sales, Asia Pacific, Japan & Greater China. "I am pleased to recognise Ricoh as the winner of the Asia Pacific SMB Managed Service Partner of the Year 2023, further underscoring their outstanding accomplishments in the Asia Pacific region."

| About Ricoh |

Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support the digital transformation of workplaces and workspaces, and optimise business performance.

Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organisational capabilities nurtured over its 85-year history. In the financial year ended March 2023, Ricoh Group had worldwide sales of 2,134 billion yen (approx. 16.0 billion USD).

It is Ricoh’s mission and vision to empower individuals to find Fulfillment through Work by understanding and transforming how people work so we can unleash their potential and creativity to realise a sustainable future.

For further information, please visit www.ricoh.com

© 2023 RICOH ASIA PACIFIC PTE LTD. All rights reserved. All referenced product names are the trademarks of their respective companies.

Source : Ricoh wins Asia Pacific SMB Managed Service Partner of the Year

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ — TooliP is a service that facilitates the instantaneous translation of patent documents through the utilization of AI language models specifically trained on patent-related content. Launched on November 13, 2023, TooliP, derived from the combination of "Tool" and "IP," represents a groundbreaking translation tool featuring an innovative AI-powered engine designed exclusively for patent document translation.

TooliP unveils real-time AI-powered patent translation service

TooliP is a service that employs deep learning technology, utilizing a training dataset comprised of approximately 100 million sentence pairs from patent specifications. Users can receive high-quality translations tailored specifically for patent-related content, encompassing specialized jargon and technical terms. Drawing from a patent database developed in collaboration with patent attorneys and professional translators, TooliP offers editing features such as a similar sentence recommendation function, word matching within sentences, and a straightforward word correction function. These capabilities facilitate more straightforward sentence verification and enhance the overall user experience.

While TooliP primarily focuses on patent document translation, its services can also be extended to general text translation. Moreover, its document translation feature supports a variety of formats (such as docx, pdf, hlz) through a user-friendly upload method. When it comes to patent specification documents, TooliP goes beyond basic translation. It analyzes the document’s overall structure and sentence forms, harnessing a extensive artificial intelligence resources to ensure more precise and accurate translations.

Lee Geon-Cheol, the developer and CEO of TooliP, is an expert with years of experience as a patent attorney. Drawing on his extensive knowledge and expertise accumulated over the years, he dedicated considerable time to research and development in collaboration with the AI department. Eventually, in 2023, he successfully launched the TooliP service, providing real-time translation and editing/viewing capabilities for patent documents based on artificial intelligence.

Translations of patent specifications require a higher level of specificity and accuracy than other specialized translation. TooliP empowers its users to streamline the translation process, enabling them to easily save approximately 80% or more of their current translation labor time. Currently, TooliP supports two-way translation between Korean and English, Korean and Japanese, and Korean and Chinese. However, the platform is set to expand its language offerings soon, including translations involving Russian, German, and French.

To celebrate the service launch, TooliP is currently offering the free use of all its services during the first month after sign-up. Additional details can be found on the company’s website or by

Users who have tried TooliP for the first time have been highly impressed by the service’s ability to generate specialized translations for patent specifications with a high level of accuracy.

TooliP has garnered attention as a specialized service that utilizes AI language models trained exclusively on patent documents.  When compared to conventional methods, TooliP enables real-time translation of patent documents with a remarkable reduction of over 80% in the time required for translating and editing patent specifications.

Source : TooliP unveils real-time AI-powered patent translation service

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ — PILLSANG Co.,Ltd. offers AllCatcher, a mobile application designed to prevent potential damage by utilizing AI to instantly block malicious URLs.

In a recent incident in Japan, personal information of 440,000 users from the widely-used messaging app ‘Line’ was compromised. Additionally, various cyber threats such as spam emails, ransomware, and phishing scams often originate from clicking on malicious URL links.

Until now, security technologies could only provide post-incident responses, lacking the capability to prevent damages proactively. In response to this challenge, South Korean artificial intelligence security specialist, PILLSANG, has launched ‘AllCatcher,’ an AI-based app designed for real-time blocking of malicious URLs.

With ‘AllCatcher’ installed, users receive immediate notifications indicating whether a URL is normal or malicious upon reception, and they can also verify it within the app. Furthermore, the app ensures the safety of seniors and children, protecting them from accidentally clicking on malicious URLs.

PILLSANG, Launches New Security Solution to Prevent ‘Phishing Sagi’ in Japan

Achieving 100,000 downloads within its first year of release in Korea, ‘AllCatcher’ has maintained a 5-star rating on the Play Store, securing the 2nd position among financial apps and the 10th position overall.

Through the ‘AllCatcher’ app, PILLSANG aims to prevent citizens from falling victim to cyber threats, contributing to global cyber security efforts by utilizing technology to enhance the Fraud Detection Systems (FDS) of banks. 

Source : PILLSANG, Launches New Security Solution to Prevent 'Phishing Sagi' in Japan

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

ROCKVILLE, Md. and SUZHOU, China, Dec. 19, 2023 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and AnHeart Therapeutics ("AnHeart"), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Priority Review Designation[1] for the New Drug Application (NDA) of taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. The CDE accepted the NDA in November 2023.

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "Taletrectinib’s potential as a best-in-class precision therapy is further underscored by the Priority Review Designation. We will continue to work with the regulatory authorities to support the review of taletrectinib with the goal of bringing this next-generation option to address unmet needs for ROS1-positive NSCLC patients in China."

Bing Yan, MD, Chief Medical Officer of AnHeart, stated: "Taletrectinib’s Priority Review Designation reinforces the urgent need for patients with ROS1-positive NSCLC who were previously treated with ROS1 TKIs in China and the significant clinical advance that taletrectinib may represent for these patients. We look forward to working with the regulatory authorities as they conduct their review of taletrectinib to hopefully bring this breakthrough investigational therapy to patients as soon as possible."

The NDA and Priority Review Designation in China are based on data from the Phase 2 TRUST-I trial (NCT04395677). Data from an interim analysis of TRUST-I were presented at the European Lung Cancer Congress (ELCC) 2023.[Link]

About ROS1-positive Non-small Cell Lung Cancer

More than one million people globally are diagnosed with NSCLC annually, the most common form of lung cancer. It is estimated that approximately 3% of people with NSCLC in China are ROS1-positive. There are two approved first-generation TKIs for people with newly diagnosed advanced or metastatic ROS1-positive NSCLC and no approved therapies for people whose ROS1-positive NSCLC has progressed following treatment with these medicines. Up to 35% of people newly diagnosed with metastatic ROS1-positive NSCLC have tumors that have spread to their brain (brain metastases), increasing up to 55% for those whose cancer has progressed following initial treatment.

About Taletrectinib

Taletrectinib is an oral, potent, brain penetrant, selective, next-generation potential best-in-class ROS1 inhibitor.

Taletrectinib is being evaluated in ROS1-positive NSCLC patients in two Phase 2 trials, TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global pivotal trial.

In March 2022, taletrectinib was granted Breakthrough Therapy Designation by the CDE of China’s NMPA for the treatment of adult patients with advanced or metastatic ROS1-positive NSCLC who have previously been treated with ROS1 TKIs as well as those who have not previously been treated by ROS1 TKIs (TKI-naïve). 

Taletrectinib has also been granted Breakthrough Therapy Designation in the United States for the treatment of ROS1-positive NSCLC by the U.S. Food and Drug Administration (FDA).

In June 2021, Innovent and AnHeart entered into an exclusive license agreement for the co-development and commercialization of taletrectinib in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent’s mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients’ lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules ), FUCASO® (Equecabtagene  Autoleucel Injection) and SINTBILO® (Tafolecimab Injection). Additionally, we have 2 NDAs under NMPA review, 6 assets in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage.

Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives.

Note:

TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.

Disclaimer: Innovent does not recommend any off-label usage.

About AnHeart Therapeutics

AnHeart Therapeutics ("AnHeart”) is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. Our lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration and the China National Medical Products Administration. AnHeart’s second investigational therapy, safusidenib, is a mIDH1-inhibitor being evaluated in Phase 2 trials for IDH1-mutant glioma.

Our mission is to improve the lives of people with cancer. We are supported by leading life sciences investors and have built an organization with deep oncology drug discovery and development expertise, with offices in New York and Shanghai. For more information, visit https://www.anhearttherapeutics.com/ or follow us on LinkedIn at https://www.linkedin.com/company/anheart-therapeutics-official/.

Innovent’s Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

[1] Priority Review Designation was established in China to accelerate the research and development of innovative drugs that have significant clinical advantages and for diseases where there is urgent clinical need. Priority Review Designation allows the CDE to prioritize the review process and evaluation resources for NDAs, which helps accelerate the market access of innovative drugs.

Source : Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network